Liquidia and United Therapeutics Announce Global Settlement Resolving All Pending Litigation

The settlement follows a September 2026 federal court ruling in favor of United Therapeutics regarding two patent infringement claims related to the use of inhaled treprostinil for PH-ILD. No safety concerns were raised.

FDA Oks sotatercept label update

The label references trial data that shows the drug as safe and effective for moderate to high-risk PAH.

Pulmovant opens Phase 3 mosliciguat study

Pulmovant is enrolling participants in its Phase 3 mosliciguat study after positive Phase 2 results.

FDA to review Ralinepag

The FDA will review United Therapeutic’s new drug application for Ralinepag, a once-daily pill to treat PAH.

Phase 1 trial shows treprostinil skin patch’s potential

Transdermal delivery could be alternative to existing treprostinil administration methods, study results suggest.

United Therapeutics Acquires Thymmune Therapeutics

United Therapeutics acquired Thymmune Therapeutics, which is developing regenerative cell therapies for potential post-transplant treatment.

Medicare, some insurers to cover OxiWear oxygen monitor

Eligible patients can now access OxiWear through Medicare and participating insurance providers. The device continuously monitors blood oxygen.

FDA approves UT’s device to assess donor lungs

The FDA gave pre-market approval to United Therapeutic’s LungFX device to assess donor lungs outside the body.

Ralinepag shows delayed disease progression in PAH study

Ralinepag met a primary goal to delay disease progression in a Phase 3 stud. The study also met several important secondary goals.

Gossamer announces topline results from Phase 3 seralutinib study

Gossamer Bio’s Phase 3 seralutinib trial narrowly missed its primary endpoint goal to show improved six-minute walk distance at week 24.

Pulmovant completes Phase 2 study enrollment for PH-ILD drug

Pulmovant has completed enrollment for its Phase 2 PHocus clinical trial to evaluate a once-daily inhaled treatment for PH-ILD.

Cereno to expand drug development focus to PH-ILD

Cereno Scientific plans to focus development of its HDAC inhibitor CS014 on PH related to interstitial lung disease.